PCN73 Cost-Effectiveness of Pembrolizumab Versus Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma (ESCC) As the Second-LINE Treatment Among the Chinese Population

Abstract

Authors

Y. Wang Y. Huang H. Shao

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×